Citius Pharmaceuticals (CTXR) Income towards Parent Company (2010 - 2026)

Citius Pharmaceuticals (CTXR) has 17 years of Income towards Parent Company data on file, last reported at -$28.1 million in Q1 2026.

• Quarterly Income towards Parent Company fell 144.19% year-over-year to -$28.1 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$55.5 million (down 27.64% YoY) and the FY2025 annual result came in at -$39.7 million, down 0.8% from the prior year.
• Income towards Parent Company declined to -$28.1 million in Q1 2026, from -$9.4 million in the prior quarter.
• In the past five years, Income towards Parent Company ranged from a high of -$3.6 million in Q4 2022 to a low of -$28.1 million in Q1 2026.
• A 5-year average of -$10.2 million and a median of -$9.2 million in 2023 frame the typical range for Income towards Parent Company.
• Annual changes were most pronounced in 2022 — Income towards Parent Company soared 61.05% — and 2023, when it plunged 156.88%.
• Tracing CTXR's Income towards Parent Company over 5 years: stood at -$3.6 million in 2022, then sank by 156.88% to -$9.2 million in 2023, then slipped by 11.38% to -$10.3 million in 2024, then grew by 8.63% to -$9.4 million in 2025, then slumped by 199.23% to -$28.1 million in 2026.
• The last three Income towards Parent Company figures came in at -$28.1 million (Q1 2026), -$9.4 million (Q4 2025), and -$8.7 million (Q3 2025), per Business Quant data.